Literature DB >> 7848976

First experience with a new echographic contrast agent.

G Cennamo1, N Rosa, G F Vallone, F Smaltino.   

Abstract

The intravenous injection of an ultrasound contrast agent can enhance signals from blood flow. Broad toxicological and pharmaceutical studies in animals confirmed the safety and efficacy of an ultrasound contrast agent made of microparticles of galactose with stabilised microbubbles in watery suspension (SH U 508 A). In this paper 10 patients with different malignant orbital and ocular tumours have been evaluated with an echo colour Doppler machine before and after the injection of SH U 508 A. An enhancement of the Doppler signals in the lesions in different degrees has been detected. This echographic contrast agent seems to be very important not only in the evaluation of vascular lesions, but also in evaluating the effectiveness of radiotherapy in malignant tumours and could spread the echographic indications in several other ophthalmic fields.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7848976      PMCID: PMC504964          DOI: 10.1136/bjo.78.11.823

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  11 in total

1.  Ultrasound contrast agents.

Authors:  R Schlief
Journal:  Curr Opin Radiol       Date:  1991-04

Review 2.  Contrast agents in diagnostic ultrasound.

Authors:  J Ophir; K J Parker
Journal:  Ultrasound Med Biol       Date:  1989       Impact factor: 2.998

3.  The findings of standardized echography for choroidal folds.

Authors:  H R Atta; S F Byrne
Journal:  Arch Ophthalmol       Date:  1988-09

4.  Left heart opacification with peripheral venous injection of a new saccharide echo contrast agent in dogs.

Authors:  M D Smith; J L Elion; R R McClure; O L Kwan; A N DeMaria
Journal:  J Am Coll Cardiol       Date:  1989-06       Impact factor: 24.094

Review 5.  Standardized echography: basic principles, clinical applications, and results.

Authors:  K C Ossoinig
Journal:  Int Ophthalmol Clin       Date:  1979

6.  Echocardiography of the aortic root.

Authors:  R Gramiak; P M Shah
Journal:  Invest Radiol       Date:  1968 Sep-Oct       Impact factor: 6.016

Review 7.  Principles of Doppler and color flow.

Authors:  P N Burns
Journal:  Radiol Med       Date:  1993-05       Impact factor: 3.469

8.  Orbital tissue differentiation with standardized echography.

Authors:  S R Byrne; J S Glaser
Journal:  Ophthalmology       Date:  1983-09       Impact factor: 12.079

9.  Duplex and color Doppler ultrasound in the differential diagnosis of choroidal tumors.

Authors:  P G Wolff-Korman; B A Kormann; G C Hasenfratz; F A Spengel
Journal:  Acta Ophthalmol Suppl       Date:  1992

10.  Diagnosis and treatment control of choroidal melanomas--the role of B-scan and Doppler-technique.

Authors:  R Guthoff; P Winkler; K Helmke; R Berger
Journal:  Acta Ophthalmol Suppl       Date:  1992
View more
  5 in total

Review 1.  Section 8--clinical relevance. American Institute of Ultrasound in Medicine.

Authors: 
Journal:  J Ultrasound Med       Date:  2000-02       Impact factor: 2.153

Review 2.  Section 6--mechanical bioeffects in the presence of gas-carrier ultrasound contrast agents. American Institute of Ultrasound in Medicine.

Authors: 
Journal:  J Ultrasound Med       Date:  2000-02       Impact factor: 2.153

Review 3.  Section 7--discussion of the mechanical index and other exposure parameters. American Institute of Ultrasound in Medicine.

Authors: 
Journal:  J Ultrasound Med       Date:  2000-02       Impact factor: 2.153

Review 4.  Section 4--bioeffects in tissues with gas bodies. American Institute of Ultrasound in Medicine.

Authors: 
Journal:  J Ultrasound Med       Date:  2000-02       Impact factor: 2.153

5.  Ocular arterial blood flow of choroidal melanoma eyes before and after stereotactic radiotherapy using Leksell gamma knife: 2 year follow up.

Authors:  P V Vécsei; K Kircher; G Nagel; S Toma-Bstaendig; I Ruhswurm; M Georgopoulos; M Zehetmayer
Journal:  Br J Ophthalmol       Date:  1999-12       Impact factor: 4.638

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.